Active Biotech Future Growth

Future criteria checks 2/6

Active Biotech is forecast to grow earnings and revenue by 56% and 110.9% per annum respectively.

Key information

56.0%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth40.4%
Revenue growth rate110.9%
Future return on equityn/a
Analyst coverage

Low

Last updated13 May 2024

Recent future growth updates

Recent updates

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Feb 19
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Jul 27
Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

May 07
Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03
We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18
We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Earnings and Revenue Growth Forecasts

OM:ACTI - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026488N/A81
12/31/202516-35N/A-351
12/31/2024N/A-43N/A-431
3/31/2024N/A-45-45-45N/A
12/31/2023N/A-46-46-46N/A
9/30/2023N/A-48-48-48N/A
6/30/2023N/A-51-50-50N/A
3/31/2023N/A-54-51-51N/A
12/31/2022N/A-58-55-55N/A
9/30/2022N/A-60-57-57N/A
6/30/2022N/A-57-55-55N/A
3/31/2022N/A-56-53-53N/A
12/31/2021N/A-50-46-46N/A
9/30/20216-38-35-35N/A
6/30/20216-35-33-33N/A
3/31/20216-32-29-29N/A
12/31/20207-32-32-32N/A
9/30/20201-39-38-38N/A
6/30/20202-40-37-37N/A
3/31/20203-36-40-40N/A
12/31/20198-34-36-36N/A
9/30/201912-32-35-35N/A
6/30/201916-31-37-37N/A
3/31/201921-35-38-38N/A
12/31/201820-37-41-41N/A
9/30/201821-88-41-41N/A
6/30/201821-88-43-43N/A
3/31/201820-103-44-44N/A
12/31/201720-109N/A-46N/A
9/30/201722-63N/A-52N/A
6/30/201721-67N/A-57N/A
3/31/201720-59N/A-61N/A
12/31/201619-60N/A-73N/A
9/30/201617-86N/A-86N/A
6/30/201618-97N/A-123N/A
3/31/201617-152N/A-187N/A
12/31/201516-194N/A-218N/A
9/30/201514-210N/A-245N/A
6/30/201512-243N/A-256N/A
3/31/201511-229N/A-243N/A
12/31/201410-232N/A-267N/A
9/30/201412-257N/A-157N/A
6/30/2014116-171N/A-159N/A
3/31/2014116-194N/A-170N/A
12/31/2013116-212N/A-102N/A
9/30/2013203-130N/A-248N/A
6/30/2013136-211N/A-256N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACTI's revenue (110.9% per year) is forecast to grow faster than the Swedish market (2.1% per year).

High Growth Revenue: ACTI's revenue (110.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACTI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.